April 27, 2012
A Merck & Co. Inc. unit prevailed Friday in a patent suit against Mylan Pharmaceuticals Inc. over its generic versions of cholesterol drugs Zetia and Vytorin, with a New Jersey federal judge ruling valid Merck's patent on an active ingredient of the drugs.
May 19, 2011
Schering Corp. on Tuesday won the dismissal of an inequitable conduct counterclaim by Mylan Pharmaceuticals Inc. in a ruling in Schering's lawsuit accusing the generic-drug maker of infringing its patents on cholesterol drug Vytorin. (A previous version of this article incorrectly stated that a ruling had been made on Mylan's antitrust counterclaims.)